Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Public ClinicalTrials.gov record NCT03892096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC).
Study identification
- NCT ID
- NCT03892096
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2019 (Actual)
- Primary completion
- Nov 15, 2023 (Actual)
- Completion
- Feb 6, 2024 (Actual)
- Last update posted
- Feb 7, 2024
2019 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CARTI Cancer Center | Little Rock | Arkansas | 72205 | — |
| Sutter Health - Palo Alto Medical Foundation | Sunnyvale | California | 94086 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| IACT Health | Columbus | Georgia | 31904 | — |
| University Medical Center | New Orleans | Louisiana | 70112 | — |
| Southeast Louisiana Veterans Health Care System | New Orleans | Louisiana | 70119 | — |
| Nebraska Cancer Center | Omaha | Nebraska | 68130 | — |
| National Translational Research Group LLC | Port Jefferson Station | New York | 11776 | — |
| Waverly Hematology Oncology | Cary | North Carolina | 27518 | — |
| Advent Health | Hendersonville | North Carolina | 28732 | — |
| Greenville Health System - Prisma Health | Greenville | South Carolina | 29605 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03892096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03892096 live on ClinicalTrials.gov.